Following these results, a phase III FIGHT-302 trial (NCT03656536) is currently underway, investigating the safety and efficacy of pemigatinib as a first-line treatment for patients with unresectable or metastatic CCA with FGFR2 fusion or rearrangement versus the current first-line systemic therapy of gemcitabine plus cisplatin (GEMCIS). The gene discussed is FGFR2; the disease is cholangiocarcinoma.